Evidence map›Paper›PMID 36377664›Full record

ArticleThe Journal of clinical investigation2022

Human Dectin-1 deficiency impairs macrophage-mediated defense against phaeohyphomycosis.

Rebecca A Drummond, Jigar V Desai, Amy P Hsu, Vasileios Oikonomou, Donald C Vinh, Joshua A Acklin, Michael S Abers, Magdalena A Walkiewicz, Sarah L Anzick, Muthulekha Swamydas and 49 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Disseminated Phaeohyphomycosis in a Patient With CARD 9 Mutation.International journal of dermatology · 2026
    Article
  4. Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Human immunity to fungal infections.The Journal of experimental medicine · 2025
    Review
  14. Article
  15. The monogenic landscape of human infectious diseases.The Journal of allergy and clinical immunology · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

59 authors at 20 institutions in 7 countries.

Rebecca A DrummondFungal Pathogenesis Section and.
Jigar V DesaiFungal Pathogenesis Section and.
Amy P HsuImmunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
Vasileios OikonomouFungal Pathogenesis Section and.
Donald C VinhDivision of Infectious Diseases, McGill University Health Centre (MUHC), and Infectious Disease Susceptibility Program, Research Institute-MUHC, Montreal, Quebec, Canada.
Joshua A AcklinDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Michael S AbersFungal Pathogenesis Section and.
Magdalena A WalkiewiczDivision of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
Sarah L AnzickResearch Technologies Branches, NIAID, NIH, Hamilton, Montana, USA.
Muthulekha SwamydasFungal Pathogenesis Section and.
Simon VautierFungal Pathogenesis Section and.
Mukil NatarajanFungal Pathogenesis Section and.
Andrew J OlerBioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, Maryland, USA.
Daisuke YamanakaLaboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Katrin D Mayer-BarberInflammation and Innate Immunity Unit, LCIM, NIAID, NIH, Bethesda, Maryland, USA.
Yoichiro IwakuraResearch Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
David BianchiNational Institute of Deafness and Other Communication Disorders (NIDCD), NIH, Bethesda, Maryland, USA.
Brian DriscollNational Institute of Deafness and Other Communication Disorders (NIDCD), NIH, Bethesda, Maryland, USA.
Ken HauckNational Institute of Deafness and Other Communication Disorders (NIDCD), NIH, Bethesda, Maryland, USA.
Ahnika KlineFungal Pathogenesis Section and.
Nicholas Sp ViallFungal Pathogenesis Section and.
Christa S ZerbeImmunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
Elise Mn FerréFungal Pathogenesis Section and.
Monica M SchmittFungal Pathogenesis Section and.
Tom DiMaggioFungal Pathogenesis Section and.
Stefania PittalugaLaboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, Maryland, USA.
John A ButmanRadiology and Imaging Sciences and.
Adrian M ZelaznyDepartment of Laboratory Medicine, NIH Clinical Center, NIH, Bethesda, Maryland, USA.
Yvonne R SheaDepartment of Laboratory Medicine, NIH Clinical Center, NIH, Bethesda, Maryland, USA.
Cesar A AriasDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Cameron AshbaughDivision of Infectious Diseases, UCSF, San Francisco, California, USA.
Maryam MahmoodDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Zelalem TemesgenDivision of Hospital Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Alexander G TheofilesDivision of Hospital Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Masayuki NigoDivision of Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Varsha MoudgalDepartment of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor, Michigan, USA.
Karen C BlochDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sean G KellyDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
M Suzanne WhitworthCook Children's Health Care System, Fort Worth, Texas, USA.
Ganesh RaoDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA.
Cindy J WhitenerDivision of Infectious Diseases, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Neema MafiDivision of Infectious Diseases, Mayo Clinic Hospital, Phoenix, Arizona, USA.
Juan Gea-BanaclocheNIAID, NIH, Bethesda, Maryland, USA.
Lawrence C KenyonDepartment of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
William R MillerDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Katia BoggianDivision of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, Switzerland.
Andrea GilbertDepartment of Pathology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Matthew SincockLCIM, NIAID, NIH, Bethesda, Maryland, USA.
Alexandra F FreemanImmunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
John E BennettWilmington Health, Wilmington, North Carolina, USA.
Rodrigo HasbunDepartment of Internal Medicine, University of Texas Health Science Center, Houston, Texas, USA.
Constantinos M MikelisDepartment of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Kyung J Kwon-ChungMolecular Microbiology Section, LCIM and.
Yasmine BelkaidMetaorganism Immunity Section, Laboratory of Host Immunity and Microbiome, NIAID, NIH, Bethesda, Maryland, USA.
Gordon D BrownMedical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom.
Jean K LimDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Douglas B KuhnsNeutrophil Monitoring Laboratory, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Steven M HollandImmunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
Michail S LionakisFungal Pathogenesis Section and.
National Institute of Allergy and Infectious Diseases · USNational Institute on Deafness and Other Communication Disorders · USNational Institutes of Health · USHouston Methodist · USIcahn School of Medicine at Mount Sinai · USMayo Clinic · USOffice of Extramural Research · USVanderbilt University Medical Center · USBaylor College of Medicine · USCook Children's Health Care System · USCritical Technologies (United States) · USDMS Imaging (France) · FRFrederick National Laboratory for Cancer Research · USInstitute of Infection and Immunity · CAMayo Clinic Hospital · USMayo Clinic in Florida · USMcGill University Health Centre · CANational Cancer Institute · USNaval Research Laboratory Information Technology DivisionPenn State Milton S. Hershey Medical Center · US

Funding

Immunopathogenesis of Fungal InfectionsZIAAI001175 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LIONAKIS, MICHAIL · 2012 to 2025
$23.9M
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVIDGE, TOR C. · 2020 to 2025
$12.0M
VENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9M
The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Elucidating the roles of systemic and mucosal complement in protection against invasive fungal infections impacting hematopoietic cell transplantR00AI141622 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI DESAI, JIGARKUMAR V · 2022 to 2023
$498k
Molecular basis of the cefazolin inoculum effectR21AI143229 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2019 to 2020
$442k
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA AI001175Medical Research Council MR/N006364/1Medical Research Council MR/N006364/2Medical Research Council MR/V033417/1NCI NIH HHS HHSN261200800001ENIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R00 AI141622NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIAID NIH HHS R21 AI143229Wellcome Trust 102705/Z/13/Z
6 · The paper itself

Abstract

Subcutaneous phaeohyphomycosis typically affects immunocompetent individuals following traumatic inoculation. Severe or disseminated infection can occur in CARD9 deficiency or after transplantation, but the mechanisms protecting against phaeohyphomycosis remain unclear. We evaluated a patient with progressive, refractory Corynespora cassiicola phaeohyphomycosis and found that he carried biallelic deleterious mutations in CLEC7A encoding the CARD9-coupled, β-glucan-binding receptor, Dectin-1. The patient's PBMCs failed to produce TNF-α and IL-1β in response to β-glucan and/or C. cassiicola. To confirm the cellular and molecular requirements for immunity against C. cassiicola, we developed a mouse model of this infection. Mouse macrophages required Dectin-1 and CARD9 for IL-1β and TNF-α production, which enhanced fungal killing in an interdependent manner. Deficiency of either Dectin-1 or CARD9 was associated with more severe fungal disease, recapitulating the human observation. Because these data implicated impaired Dectin-1 responses in susceptibility to phaeohyphomycosis, we evaluated 17 additional unrelated patients with severe forms of the infection. We found that 12 out of 17 carried deleterious CLEC7A mutations associated with an altered Dectin-1 extracellular C-terminal domain and impaired Dectin-1-dependent cytokine production. Thus, we show that Dectin-1 and CARD9 promote protective TNF-α- and IL-1β-mediated macrophage defense against C. cassiicola. More broadly, we demonstrate that human Dectin-1 deficiency may contribute to susceptibility to severe phaeohyphomycosis by certain dematiaceous fungi.

Indexed as

beta-GlucansPhaeohyphomycosisAnimalsCARD Signaling Adaptor ProteinsDectin-1HumansLectins, C-TypeMacrophagesMaleMiceTumor Necrosis Factor-alphabeta-GlucansCARD9 protein, humanCard9 protein, mouseCARD Signaling Adaptor ProteinsCLEC7A protein, humanClec7a protein, mouseDectin-1Lectins, C-TypeTumor Necrosis Factor-alphaFungal infectionsGenetic variationImmunologyInfectious diseaseInnate immunity

Identifiers

PMID36377664
PMCPMC9663159
OpenAlexW4308992051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.